Different clinical trials with IL1Ra (anakinra) for adult patients or human monoclonal anti-IL-1β antibody (canakinumab) in pediatric T1DM patients have not been effective in maintaining B-cell function; however, the present meta-analysis showed a critical time point during T1DM progression that could be important to keep in mind for the administration of treatments. Here, IL1B is linked to type 1 diabetes mellitus.